Literature DB >> 16624404

Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.

Girish Venkataraman1, Tazeen Maududi, Fulya Ozpuyan, Hakki I Bahar, Keith F Izban, Jiang-Zon Qin, Serhan Alkan.   

Abstract

Typical mantle cell lymphoma (MCL) is a distinct B-cell non-Hodgkin's lymphoma associated with over-expression of cyclin D1 related to translocation between the IgH and BCL-1 genes. Due to the important functional interaction between cyclin D1 and cyclin dependent kinases, cyclin dependent kinase inhibitors such as flavopiridol are under consideration for treatment of patients with MCL. The present study investigated the in vitro effects of flavopiridol on the MCL cell line (JeKo-1). Flavopiridol at a dose of 10nmol/L induced apoptosis by 6h of treatment as noted by flow cytometric analysis, morphologic examination and Western blotting. The cleavage of procaspase-3 and PARP and the decrease of flavopiridol-induced apoptosis by pan-caspase inhibition suggested that the caspase pathway serves an important role in the apoptotic process. Furthermore, MCL cells exposed to flavopiridol showed down regulation of key cell cycle proteins acting at the restriction point control between the G1 and S phases. The onset of flavopiridol-induced apoptosis also coincided with the down regulation of Mcl-1, anti-apoptotic protein. Collectively, our data indicates that flavopiridol may have significant therapeutic potential in the context of MCL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624404     DOI: 10.1016/j.leukres.2006.03.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

Review 1.  Novel agents in mantle cell lymphoma.

Authors:  Marcus S Noel; Jonathan W Friedberg; Paul M Barr
Journal:  Best Pract Res Clin Haematol       Date:  2012-04-30       Impact factor: 3.020

2.  Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.

Authors:  Jeffrey A Jones; Amy S Rupert; Ming Poi; Mitch A Phelps; Leslie Andritsos; Robert Baiocchi; Don M Benson; Kristie A Blum; Beth Christian; Joseph Flynn; Sam Penza; Pierluigi Porcu; Michael R Grever; John C Byrd
Journal:  Am J Hematol       Date:  2013-09-30       Impact factor: 10.047

Review 3.  Novel agents for B-cell non-Hodgkin lymphoma: science and the promise.

Authors:  Kevin Tay; Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood Rev       Date:  2010-02-11       Impact factor: 8.250

4.  Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

Authors:  Rong Chen; Sherri Chubb; Tiewei Cheng; Rachael E Hawtin; Varsha Gandhi; William Plunkett
Journal:  Cancer Res       Date:  2010-07-27       Impact factor: 12.701

5.  Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis.

Authors:  Jennifer B Dennison; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Br J Haematol       Date:  2009-08-25       Impact factor: 6.998

Review 6.  Overview of CDK9 as a target in cancer research.

Authors:  Fatima Morales; Antonio Giordano
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 7.  Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma.

Authors:  Paul J Bröckelmann; Mathilde R W de Jong; Ron D Jachimowicz
Journal:  Cells       Date:  2020-10-14       Impact factor: 6.600

8.  RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.

Authors:  Shiri Weinstein; Rafi Emmanuel; Ashley M Jacobi; Avigdor Abraham; Mark A Behlke; Andrew G Sprague; Tatiana I Novobrantseva; Arnon Nagler; Dan Peer
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

9.  P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Authors:  Nitesh P Shirsath; Sonal M Manohar; Kalpana S Joshi
Journal:  Mol Cancer       Date:  2012-10-18       Impact factor: 27.401

Review 10.  Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.

Authors:  Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.